Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

[Examination of ERCC1 expression in lung cancer patients treated with platinum-based chemotherapy].

Moldvay J, Pápay J, Puskás R, Furák J, Losonczy G, Matolcsy A.

Magy Onkol. 2011 Jun;55(2):105-9. doi: MagyOnkol.2011.55.2.105. Epub 2011 Feb 7. Hungarian.

2.

Decreased ERCC1 Expression After Platinum-Based Neoadjuvant Chemotherapy in non-Small Cell Lung Cancer.

Podmaniczky E, Fábián K, Pápay J, Puskás R, Gyulai M, Furák J, Tiszlavicz L, Losonczy G, Tímár J, Moldvay J.

Pathol Oncol Res. 2015 Apr;21(2):423-31. doi: 10.1007/s12253-014-9839-x. Epub 2014 Sep 7.

PMID:
25194563
3.

Platinum-based chemotherapy in lung cancer affects the expression of certain biomarkers including ERCC1.

Pápay J, Sápi Z, Egri G, Gyulai M, Szende B, Losonczy G, Tímár J, Moldvay J.

Pathol Oncol Res. 2009 Sep;15(3):445-50. doi: 10.1007/s12253-009-9155-z.

PMID:
19253035
4.

Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy.

Ronchi CL, Sbiera S, Kraus L, Wortmann S, Johanssen S, Adam P, Willenberg HS, Hahner S, Allolio B, Fassnacht M.

Endocr Relat Cancer. 2009 Sep;16(3):907-18. doi: 10.1677/ERC-08-0224. Epub 2009 Feb 24.

5.

The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer.

Steffensen KD, Waldstrøm M, Jakobsen A.

Int J Gynecol Cancer. 2009 Jul;19(5):820-5. doi: 10.1111/IGC.0b013e3181a12e09.

PMID:
19574766
6.

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC; IALT Bio Investigators.

N Engl J Med. 2006 Sep 7;355(10):983-91.

7.

Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy.

Azuma K, Komohara Y, Sasada T, Terazaki Y, Ikeda J, Hoshino T, Itoh K, Yamada A, Aizawa H.

Cancer Sci. 2007 Sep;98(9):1336-43. Epub 2007 Jul 19.

8.

Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.

Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, Aizawa H.

Lung Cancer. 2009 Jun;64(3):326-33. doi: 10.1016/j.lungcan.2008.09.002. Epub 2008 Nov 1.

PMID:
18977553
9.

[Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].

Qian XP, Liu BR, Shi MQ, Liu XZ, Hu WJ, Zou ZY, Wei J.

Zhonghua Zhong Liu Za Zhi. 2009 Jan;31(1):33-7. Chinese.

PMID:
19538866
10.

[ERCC1 expression and outcomes of neo-adjuvant chemotherapy in elderly patients with non-small cell lung cancer].

Li GF, Deng SJ, Weng WW, Guo G, Chen N.

Nan Fang Yi Ke Da Xue Xue Bao. 2010 Sep;30(9):2131-3. Chinese.

11.

ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.

Hwang IG, Ahn MJ, Park BB, Ahn YC, Han J, Lee S, Kim J, Shim YM, Ahn JS, Park K.

Cancer. 2008 Sep 15;113(6):1379-86. doi: 10.1002/cncr.23693.

12.

ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.

Olaussen KA, Mountzios G, Soria JC.

Curr Opin Pulm Med. 2007 Jul;13(4):284-9. Review.

PMID:
17534174
13.

Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer.

Steffensen KD, Waldstrøm M, Jeppesen U, Brandslund I, Jakobsen A.

Int J Gynecol Cancer. 2008 Jul-Aug;18(4):702-10. Epub 2007 Oct 24.

PMID:
17961161
14.

Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.

Kim SH, Kwon HC, Oh SY, Lee DM, Lee S, Lee JH, Roh MS, Kim DC, Park KJ, Choi HJ, Kim HJ.

Am J Clin Oncol. 2009 Feb;32(1):38-43. doi: 10.1097/COC.0b013e31817be58e.

PMID:
19194123
15.

Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy.

Sodja E, Knez L, Kern I, Ovčariček T, Sadikov A, Cufer T.

Eur J Cancer. 2012 Dec;48(18):3378-85. doi: 10.1016/j.ejca.2012.06.011. Epub 2012 Jul 12.

PMID:
22795264
16.

The place of excision repair cross complementation 1 (ERCC1) in surgically treated non-small cell lung cancer.

Breen D, Barlési F.

Eur J Cardiothorac Surg. 2008 May;33(5):805-11. doi: 10.1016/j.ejcts.2008.01.067. Epub 2008 Mar 14. Review.

PMID:
18342529
17.

Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer.

Okuda K, Sasaki H, Dumontet C, Kawano O, Yukiue H, Yokoyama T, Yano M, Fujii Y.

Lung Cancer. 2008 Oct;62(1):105-12. doi: 10.1016/j.lungcan.2008.02.021. Epub 2008 Apr 18.

PMID:
18395930
18.

Comparison of two ERCC1 antibodies as prognostic and predictive biomarkers for early non-small cell lung cancer.

Muley TR, Sianidou M, Thomas M, Bischoff H, Dienemann H, Meister M, Schneider MA, Schnabel PA, Warth A.

Anticancer Res. 2014 Jul;34(7):3707-13.

PMID:
24982391
19.

Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy.

Fareed KR, Al-Attar A, Soomro IN, Kaye PV, Patel J, Lobo DN, Parsons SL, Madhusudan S.

Br J Cancer. 2010 May 25;102(11):1600-7. doi: 10.1038/sj.bjc.6605686. Epub 2010 May 11.

20.

The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis.

Chen S, Zhang J, Wang R, Luo X, Chen H.

Lung Cancer. 2010 Oct;70(1):63-70. doi: 10.1016/j.lungcan.2010.05.010. Epub 2010 Jun 11.

PMID:
20541281

Supplemental Content

Support Center